Trial · NCT01015833
Adverse events536
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 536
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) | 10 | 167 | 11 |
| other | Anemia | Blood and lymphatic system disorders | Arm II (Sorafenib Tosylate) | 8 | 171 | 8 |
| other | Blood and lymphatic system disorders - Other, specify | Blood and lymphatic system disorders | Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) | 0 | 167 | 0 |
| other | Blood and lymphatic system disorders - Other, specify | Blood and lymphatic system disorders | Arm II (Sorafenib Tosylate) | 1 | 171 | 2 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) | 5 | 167 | 7 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm II (Sorafenib Tosylate) | 0 | 171 | 0 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) | 1 | 167 | 1 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Arm II (Sorafenib Tosylate) | 0 | 171 | 0 |
| other | Hemolysis | Blood and lymphatic system disorders | Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) | 1 | 167 | 1 |
| other | Hemolysis | Blood and lymphatic system disorders | Arm II (Sorafenib Tosylate) | 0 | 171 | 0 |
| other | Thrombotic thrombocytopenic purpura | Blood and lymphatic system disorders | Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) | 1 | 167 | 1 |
| other | Thrombotic thrombocytopenic purpura | Blood and lymphatic system disorders | Arm II (Sorafenib Tosylate) | 0 | 171 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) | 1 | 167 | 5 |
| other | Atrial fibrillation | Cardiac disorders | Arm II (Sorafenib Tosylate) | 0 | 171 | 0 |
| other | Chest pain - cardiac | Cardiac disorders | Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) | 0 | 167 | 0 |
| other | Chest pain - cardiac | Cardiac disorders | Arm II (Sorafenib Tosylate) | 2 | 171 | 3 |
| other | Left ventricular failure | Cardiac disorders | Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) | 0 | 167 | 0 |
| other | Left ventricular failure | Cardiac disorders | Arm II (Sorafenib Tosylate) | 1 | 171 | 1 |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Arm I (Doxorubicin Hydrochloride, Sorafenib Tosylate) | 7 | 167 | 7 |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Arm II (Sorafenib Tosylate) | 0 | 171 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01015833/events